

09/830037

Rec'd PCT/PTO 20 APR 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gordon J. DOW et al  
International Appln. Serial No.: PCT/GB99/03472

Group Art Unit:

International Appln. Filed: 20 October 1999

Examiner:

For: FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR ACTIVITY

Commissioner for Patents  
Washington, D.C. 20231

#4  
LW  
7-5-01

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed  
 Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))  
 A copy of the International Search Report which issued on International Application No. PCT/GB99/03472 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B.  The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C.  The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but **before** the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[ ] Applicant [REDACTED] by certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


[ ] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

[ ] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[ ] Please charge required fees to Deposit Account No. 07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,



James P. RIEK

Registration No. 39,009

Date: April 20, 2001  
GlaxoSmithKline  
Corporate Intellectual Property Dept.  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919) 483-1240  
Facsimile: (919) 483-7988